ATV Plus Indications/Uses

It is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.
Amlodipine: Hypertension.
Coronary Artery Disease (CAD): Chronic Stable Angina; Vasospastic Angina (Prinzmetal's or Variant Angina); Angiographically Documented CAD.
Atorvastatin: Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended, as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD (Coronary Heart Disease) or multiple risk factors for CHD (Coronary Heart Disease), the atorvastatin component can be started simultaneously with diet.
Prevention of Cardiovascular Diseases: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDLC or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke; Reduce the risk for revascularization procedures and angina.
In patients with type 2 diabetes and without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking or hypertension, it is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke.
In patients with clinically evident coronary heart disease, it is indicated to: Reduce the risk of non-fatal myocardial infarction; Reduce the risk of fatal and non-fatal stroke; Reduce the risk for revascularization procedures; Reduce the risk of hospitalization for CHF (Congestive Heart Failure); Reduce the risk of angina.
Heterozygous Familial and Nonfamilial Hyperlipidaemia: Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb).
Elevated Serum TG Levels: Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV).
Primary Dysbetalipoproteinemia: Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet.
Homozygous Familial Hypercholesterolemia: Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Pediatric Patients: Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥190 mg/dL or; b. LDL-C remains ≥160 mg/dL and: There is a positive family history of premature cardiovascular disease or; Two or more other CVD risk factors are present in the pediatric patients.